MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Venture Capital: Risk Capital_Angel, Venture, Sovereign Wealth Investor Companies & Organizations
Portfolio Companies: Laidlaw
Fennec Pharmaceuticals Inc (NASDAQ: FENC)*
Organization & Developments: Fennec Pharmaceuticals
Parents
Fennec Pharmaceuticals Inc (NASDAQ: FENC)*
Children
2018: Fennec Pharmaceuticals: SIOP 2018 Provides Insight Into Pedmark Trajectory _seekingalpha.com
2018: Fennec Pharmaceuticals’ Cisplatin-Ototoxicity Treatment Given Breakthrough Therapy Designation
2019: Post-FDA Meeting, The Path Ahead Of Fennec Is Clear - Fennec Pharmaceuticals, Inc. (NASDAQ:FENC)
2020: Fennec Pharmaceuticals Reports Complete Response Letter Issuance from FDA for Pedmark Application
2020: Fennec Pharmaceuticals: Time Is Ticking_seekingalpha.com
2021: Fennec Pharmaceuticals: Will Pedmark Make It To Market At Second Time Of Asking?
2022: Fennec finally pushes drug to prevent chemotherapy-induced hearing loss across the FDA finish line
2022: Fennec Pharmaceuticals (FENC) Investor Presentation - Slideshow_ seekingalpha.com
2022: Fennec: Pedmark Approval Can Help Minimize Chemo-Induced Hearing Loss In Pediatric Cancer Patients_ seekingalpha.com
2023: Navigating Financial Challenges To Dominate Market
2024: Fennec Pharmaceuticals: Great Sales Progress - Not Yet Reflected In Stock Price
2024: Fennec: Operational Challenges Persist Despite Improved Financial Position
Jumps
Finance & Acquisitions: Fennec Pharmaceuticals
Key People: Fennec Pharmaceuticals